Intravenous immunoglobulin for severe gastrointestinal manifestation of Henoch-Schönlein purpura refractory to corticosteroid therapy

스테로이드 치료에 반응하지 않는 심한 위장관 증세의 Henoch-Schönlein 자반증 환아에서 정맥 면역글로불린 치료

  • Yang, Hye Ran (Department of Pediatrics, College of Medicine, Seoul National University) ;
  • Choi, Won Jung (Department of Pediatrics, College of Medicine, Seoul National University) ;
  • Ko, Jae Sung (Department of Pediatrics, College of Medicine, Seoul National University) ;
  • Seo, Jeong Kee (Department of Pediatrics, College of Medicine, Seoul National University)
  • 양혜란 (서울대학교 의과대학 소아과학교실) ;
  • 최원정 (서울대학교 의과대학 소아과학교실) ;
  • 고재성 (서울대학교 의과대학 소아과학교실) ;
  • 서정기 (서울대학교 의과대학 소아과학교실)
  • Received : 2006.01.31
  • Accepted : 2006.05.02
  • Published : 2006.07.15

Abstract

Purpose : $Henoch-Sch{\ddot{o}}nlein$ purpura(HSP) is a systemic vasculitis involving small vessels of skin, gastrointestinal(GI) tract and kidney. Digestive involvement of HSP can be serious with massive GI bleeding, perforation, and intussusception. However, some patients do not respond to conventional corticosteroid therapy. In this study, we investigated the efficacy of intravenous immunoglobulin (IVIG) for serious digestive manifestations not responding to steroid. Methods : From April 1999 to January 2005, 22 children diagnosed as HSP with severe GI symptoms were included. Initially, all patients were treated with intravenous methylprednisolone. IVIG 2 g/kg of body weight was infused in children refractory to steroid therapy. Clinical data were reviewed retrospectively. Results : Among 22 children, 12 children underwent IVIG therapy. The mean duration of corticosteroid therapy was $5.61{\pm}4.9$ days before IVIG therapy, and 11 of 12 patients experienced disappearance of GI manifestations after the initiation of IVIG infusion. In one patient, IVIG was ineffective in relieving abdominal pain, but melena subsided. Comparison of the duration of hospitalization between IVIG group and corticosteroid group revealed no significant difference($12.8{\pm}7.6$ days vs. $13.2{\pm}7.8$ days, P=0.777). But, the total duration of abdominal pain decreased in IVIG group although the difference between two groups was not significant($8.8{\pm}8.1$ days vs. $14.8{\pm}16.9$ days, P=0.306). Among 10 children treated with steroid only, 2 children were operated for bowel perforation and intussusception. In contrast, there was no perforation in 12 children who underwent IVIG therapy. Conclusion : IVIG could be the alternative therapy to corticosteroids in children with severe digestive manifestations of HSP.

목 적 : HSP는 피부, 관절, 위장관, 신장을 포함한 전신의 소혈관을 침범하는 혈관염이다. HSP의 위장관 증상은 때로 다량의 위장관 출혈, 장천공, 장중첩 등의 위중한 형태로 나타날 수 있는데, 이 중 일부 환자는 corticosteroid 치료에도 불구하고 증상이 호전되지 않는 경우가 있다. 저자들은 심한 위장관 증세를 보이면서 스테로이드에 반응하지 않는 HSP 환아에서 IVIG 치료의 효과를 알아보고자 하였다. 방 법 : 1999년 4월부터 2005년 1월까지 심각한 위장관 증상으로 입원한 22명의 HSP 환아들의 의무기록을 조사하였다. 이들 모두에서 처음엔 methylprednisolone(2 mg/kg)을 정맥 투여하였으며, 스테로이드 치료에 반응이 없는 환아들을 대상으로 하여 IVIG(2 g/kg)을 투여하였다. 결 과 : 대량의 위장관 출혈과 복통 등이 동반된 심한 위장관 증상을 나타낸 22명의 환아(연령 : 2.3-15세, 성별 M : F=12 : 10)중에 12명이 스테로이드 치료에도 불구하고 증상이 호전되지 않아 고용량 IVIG 치료를 받았다. IVIG 투여 전, methylprednisolone 정맥주사의 평균 투여기간은 $5.6{\pm}4.9$일이었으며 12명 중 11명에서 IVIG 투여 후 1시간에서 5일 사이에 위장관 증상이 호전되었다. 나머지 1명은 IVIG 투여 후에도 복통이 있었으나, 혈변은 소실되었다. IVIG을 투여받은 환아들과 corticosteroid만을 투여받은 환아들간에 입원기간의 차이는 없었다($12.8{\pm}7.6$일 vs. $13.2{\pm}7.8$일, P=0.777). 복통이 지속되었던 총기간은 IVIG 투여군이 짧았으나 통계적으로는 유의하지 않았다($8.8{\pm}8.1$일 vs. $14.8{\pm}16.9$일, P=0.306). Methylprednisolone 정맥주사만을 단독으로 치료받은 10명 중 2명(20%)은 장천공으로 수술을 받았으나, IVIG 투여군 12명에서는 장천공이 전혀 발생하지 않았다. 결 론 : 심한 위장관 침범이 있는 HSP 환아의 복부증상이 기존의 스테로이드 치료에도 불구하고 호전되지 않을 때에는 고용량 정맥 면역글로불린 투여를 고려해 볼 수 있을 것이다.

Keywords

References

  1. Rostoker G. Schölein-Henoch Purpura in children and adults. BioDrugs 2001;15:99-138 https://doi.org/10.2165/00063030-200115020-00004
  2. Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis : speculation or evidence? Clin Rev Allergy Immunol 2005;29:237-46 https://doi.org/10.1385/CRIAI:29:3:237
  3. Heldrich FJ, Minkin S, Gatdula CL. Intravenous immunoglobulin in Henoch-Schölein purpura : a case study. Md Med J 1993;42:577-9
  4. Hamidou MA, Pottier MA, Dupas B. Intravenous immunoglobulin in Henoch-Schölein purpura. Ann Intern Med 1996;125:1013-4
  5. Ruellan A, Khatibi M, Staub T, Martin T, Storck D, Christmann D. Rheumatoic purpura and intravenous immunoglobulins. Rev Med Interne 1997;18:727-9 https://doi.org/10.1016/S0248-8663(97)83754-X
  6. Lamireau T, Rebouissoux L, Hehunstre JP. Intravenous immunoglobulin therapy for severe digestive manifestations of Henoch-Schölein purpura. Acta Paediatr 2001;90:1081-2
  7. Kim YO, Lee CY. IV-gamma globulin therapy for severe abdominal pain refractory to steroid therapy. J Korean Society Pediatr Nephrol 1997;1:176-8
  8. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schölein purpura. Arthritis Rheum 1990;33:1114-21 https://doi.org/10.1002/art.1780330809
  9. Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Schölein purpura : a comparison between the 2 disorders. J Rheumatol 1992;19: 721-8
  10. Feldt R, Stickler G. The gastro-intestinal manifestations of anaphylactoid purpura in children. Staff Meetings of the Mayo Clinic 1962;37:465-73
  11. Saulsbury F. Henoch-Schölein purpura in children. Medicine 1999;78:395-409 https://doi.org/10.1097/00005792-199911000-00005
  12. Lin SJ, Chao HC, Huang JL. Gastrointestinal involvement as the initial manifestation in children with Henoch-Schölein purpura- Clinical analysis of 27 cases. Acta Paediatr Sin 1998;39:186-90
  13. Choong CK, Beasley SW. Intraabdominal manifestations of Henoch-schölein purpura. J Pediatr Child Health 1998;34: 405-9 https://doi.org/10.1046/j.1440-1754.1998.00263.x
  14. Diaz C. Schölein-Henoch purpura and pancreatitis. Dig Dis Sci 1995;40:750-1 https://doi.org/10.1007/BF02064974
  15. Cho CS, Min JK, Park SH, Yang HI, Lee SH, Choi YJ, et al. Protein losing enteropathy associated with Henoch- Schölein purpura in a patient with rheumatoid arthritis. Scand J Rheumatol 1996;25:334-6 https://doi.org/10.3109/03009749609104068
  16. Cull D, Rosario V, Lally K, Ratner I, Mahour GH. Surgical implications of Henoch-Schölein purpura. J Pediatr Surg 1990;25:741-3 https://doi.org/10.1016/S0022-3468(05)80009-0
  17. Haroon M. should children with Henoch-Schölein purpura and abdominal pain be treated with steroids? Arch Dis Child 2005;90:1196-8 https://doi.org/10.1136/adc.2005.077743
  18. Rosenblum N, Winter H. Steroid effects on the course of abdominal pain in children with Henoch-Schölein purpura. Pediatrics 1987;79:1018-21
  19. Szer I. Henoch-Schölein purpura when and how to treat. J Rheumatol 1996;23:1661-5
  20. Dwyer JM. Manipulating the immune system with immunoglobulins. N Engl J Med 1992;326:107-14 https://doi.org/10.1056/NEJM199201093260206
  21. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-89 https://doi.org/10.7326/0003-4819-112-4-278
  22. Kusuda A, Migita K, Tsuboi M, Degawa M, Matsuoka N, Tominaga M, et al. Successful treatment of adult onset Henoch-Schölein purpura nephritis with high dose immunoglobulins. Int Med 1999;38:376-9 https://doi.org/10.2169/internalmedicine.38.376
  23. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippon C, Deforges L, et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schölein purpura. Ann Intern Med 1994;120:476-84 https://doi.org/10.7326/0003-4819-120-6-199403150-00005
  24. Villarreal IR, Ortega O, Vigil A, Gallar P, Oliet A, Garcia- Rubiales A, et al. Henoch-Schölein nephritis. Adverse effect of treatment with intravenous immunoglobulin. Nephrol Dial Transplant 1999;14:795-7 https://doi.org/10.1093/ndt/14.3.795a
  25. Blanco R, Gonzalez-Gay MA, Ibanez D, Sanchez-Andrade A, Gonzalez-Vela C. Paradoxical and persistent renal impairment in Henoch-Schölein purpura after high-dose immunoglobulin therapy. Nephron 1997;76:247-8 https://doi.org/10.1159/000190187
  26. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney-a two-edged sword. Semin Arthritis Rheum 2004;34:593-601 https://doi.org/10.1016/j.semarthrit.2004.06.003